ProQR Therapeutics Receives Buy Rating Upgrade from StockNews.com

On a recent Saturday, investment analytics firm StockNews.com revised its rating on ProQR Therapeutics NASDAQ:PRQR, lifting the biopharmaceutical company's status from a 'hold' to a 'buy'. This bullish stance by StockNews.com reflects a growing confidence in the company among market analysts.

Analyst Sentiments on ProQR Therapeutics

ProQR Therapeutics, while certainly now on the radar with its 'buy' rating, has seen a variety of opinions from other research firms. Citigroup, for instance, adjusted its target price from $2.10 to $1.80 but maintained a 'buy' rating for the stock. Similarly, Raymond James lowered its target price from $5.00 to $4.00 while still advocating for an 'outperform' rating. Chardan Capital shifted its viewpoint from 'neutral' to 'buy', setting a target of $2.00 for ProQR's shares. Furthermore, HC Wainwright reaffirmed their 'buy' rating with a $5.00 price target. These assessments culminate in an average target price of $3.72 and a strong consensus 'buy' recommendation from seven analysts, as aggregated data from MarketBeat.com indicates.

Market Performance of ProQR Therapeutics

The trading session prior to the weekend saw NASDAQ:PRQR shares open at $1.36. The company holds a market capitalization of approximately $109.92 million, with a PE ratio standing at -2.89 and a rather low beta value of 0.08, suggesting less volatility relative to the market. ProQR Therapeutics also maintains a 50-day simple moving average of $1.37 and a more extensive two-hundred day simple moving average of $1.61. A considerable debt-to-equity ratio of 0.06 alongside a quick ratio of 5.71 and a current ratio of 4.68 are also noteworthy. The shares have a recorded fifty-two week low of $0.90 and a peak of $3.85.

Institutional Investors and ProQR Therapeutics

Notable shifts in the company's shares by institutional investors and hedge funds have occurred recently. Tower Research Capital LLC TRC significantly increased its holdings by 164.8%, now owning 14,132 shares valued at around $30,000 after an additional purchase of 8,796 shares. Similarly, Two Sigma Securities LLC established a new position valued at $41,000. Other firms, including Belvedere Trading LLC, Virtu Financial LLC, and Mariner LLC, have also taken new positions in the shares of ProQR Therapeutics, with their investments ranging from $42,000 to $68,000. Institutional investors currently hold 26.15% of the stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is vested in the discovery and development of novel therapies. Its pipeline includes AX-0810, targeting Na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases, and AX-1412, targeting Beta-1,4-galactosyltransferase 1 (B4GALT1) for addressing cardiovascular diseases (CVDs).

Buy, Upgrade, Analysis